Methods of treating cancer by administering antigen-binding molecules comprising a TNF family ligand trimer

US11306154B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Maria Amann · Stintenberger Straße, CH
• Peter Bruenker · Hittnau, CH
• Christina Claus · Ennetbaden, CH
• Claudia Ferrara Koller · Schlieren, CH
• Sandra Grau-Richards · Schlieren, CH
• Christian Klein · Iffeldorf, DE
• Viktor Levitski · Schlieren, CH
• Ekkehard Moessner · Kreuzlingen, CH
• Joerg Thomas Regula · Munich, DE
• Pablo Umana · Wollerau, CH

Key dates

• Filing date: Jul 25, 2019
• Grant date: Apr 19, 2022
• Expiry date: Jul 25, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.